戊二醛250   UCARCIDE(TM) 250 Antimicrobial    OHC(CH2)3CHO
成分component 　　　CAS#　　　　含量Amount
Glutaraldehyde　　　111-30-8 　　　　50.0%
Water　　　　　　　7732-18-5　　　<=50.0%
Methanol　　　　　　67-56-1　　　　<=0.5%


Advantages:
- Broad spectrum biocide
- Highly effective against bacteria, fungi and yeast
- Effective over a broad pH range
- Exhibits high efficacy at low concentrations


Physical and Chemical Properties
Appearance
Physical State  Liquid.
Color  Clear
Odor  Fruity
Odor Threshold < 1 ppb Literature
pH 3.1 - 4.5 ASTM E70
Melting Point  Not applicable to liquids
Freezing Point  -18 °C (0 °F) OECD 102
Boiling Point (760 mmHg) 100.7 °C (213.3 °F) OECD 103 .



菠蘿蛋白酶  Bromelain

Bromelain is an enzyme extract derived from the stems of pineapples, although it exists in all parts of the fresh plant and fruit. The extract has a history of folk medicine use. As a culinary ingredient, it may be used as a meat tenderizer.

The term "bromelain" may refer to either of two protease enzymes extracted from the plants of the family Bromeliaceae, or it may refer to a combination of those enzymes along with other compounds produced in an extract.

Although tested in a variety of folk medicine and research models for its possible efficacy against diseases, the only approved clinical application for bromelain was issued in 2012 by the European Medicines Agency for a topical medication called NexoBrid used to remove dead tissue in severe skin burns

Extract components：
Bromelain extract is a mixture of protein-digesting (proteolytic) enzymes and several other substances in smaller quantities. The proteolytic enzymes are sulfhydryl proteases; a free sulfhydryl group of a cysteine amino acid side chain is required for function. The two main enzymes are:
- Stem bromelain
- Fruit bromelain

Potential medical uses
A concentrate of proteolytic enzymes enriched in bromelain is approved in Europe for the debridement (removal of dead tissue) of severe burn wounds under the trade name NexoBrid.
Systemic enzyme therapy (consisting of combinations of proteolytic enzymes such as bromelain, trypsin, chymotrypsin, and papain) has been investigated in Europe to evaluate the efficacy in breast, colorectal, and plasmacytoma cancer patients.